Alnylam Pharmaceuticals, Inc.

ALNY

US02043Q1076

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 17:35:44 09/07/2025 BST			5-day change	1st Jan Change
319.26 ^USD	+0.55%		-3.03%	+35.89%

07-08	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09:20 AM
07-07	RBC Raises Price Target on Alnylam Pharmaceuticals to $350 From $330, Keeps Outperform Rating	MT

UBS Raises Alnylam Pharmaceuticals' Price Target to $308 From $288, Buy Rating Maintained

Published on 19/08/2024 at 15:47, updated on 19/08/2024 at 15:53

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09:20 AM	07-08
RBC Raises Price Target on Alnylam Pharmaceuticals to $350 From $330, Keeps Outperform Rating	07-07	MT
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell 3000E Value Index	06-30	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell Midcap Value Index	06-30	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell 3000 Value Index	06-30	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell Small Cap Comp Value Index	06-30	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell 1000 Value Index	06-30	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell Small Cap Comp Value Benchmark	06-29	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell 3000E Value Benchmark	06-29	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell 3000 Value Benchmark	06-29	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell Midcap Value Benchmark	06-29	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell 1000 Value Benchmark	06-29	CI
Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer	06-18	CI
Alnylam Gets EU Approval for RNAi Drug to Treat Transthyretin Amyloidosis With Cardiomyopathy	06-09	MT
Alnylam Receives European Commission Approval for AMVUTTRA®? for the Treatment of ATTR Amyloidosis with Cardiomyopathy	06-09	CI
Transcode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board	05-28	CI
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,124,217, According to a Recent SEC Filing	05-19	MT
Alnylam Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 11:20 AM	05-14
Alnylam Pharmaceuticals, Inc. to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the Helios-B Phase 3 Study Results at Heart Failure 2025 Congress	05-12	CI
Alnylam To Share Progress Across Its Transthyretin Amyloidosis Franchise Including Additional Analyses Of The Helios-B Phase 3 Study Results At Heart Failure 2025 Congress	05-12	RE
UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating	05-02	MT
Alnylam Q1 Non-GAAP Net Loss Narrows, Revenue Rises	05-01	MT
Alnylam Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 01, 2025	05-01
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-01	CI
Earnings Flash (ALNY) Alnylam Pharmaceuticals Posts Q1 Revenue $594.2M, vs. FactSet Est of $588.4M	05-01	MT

Chart Alnylam Pharmaceuticals, Inc.

Duration

Period

ALNY: Dynamic Chart

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.

Employees

2,230

Sector

Pharmaceuticals

Calendar

07-30 - Q2 2025 Earnings Release (Projected)

More about the company